Comparison of PD-L1 Immunostain Concordance of SP263 and SP142 Across Different Tumor Types

被引：0
|
作者：
Nakasaki, Manando [1 ]
Fadare, Oluwole [1 ]
Patel, Sandip [1 ]
Hansel, Donna [1 ]
机构：
[1] Univ Calif San Diego, La Jolla, CA 92093 USA
来源：
LABORATORY INVESTIGATION | 2017年 / 97卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
2140
引用
收藏
页码：532A / 532A
页数：1
相关论文
共 50 条
  • [31] Concordance of tumor cell (TC) and immune cell (IC) staining with Ventana SP142, Ventana SP263, Dako 28-8 and Dako 22C3 PD-L1 IHC tests in NSCLC patient samples.
    Scott, Marietta L.
    Ratcliffe, Marianne J.
    Sharpe, Alan
    Barker, Craig
    Scorer, Paul
    Rebelatto, Marlon
    Al-Masri, Hytham
    Walker, Jill
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [32] Interobserver Variation of PD-L1 (SP142) Immunohistochemistry Interpretation in Breast Carcinoma
    Hoda, Raza
    Brogi, Edi
    D'Alfonso, Timothy
    Grabenstetter, Anne
    Giri, Dilip
    Hanna, Matthew
    Kuba, M. Gabriela
    Murray, Melissa
    Vallejo, Christina
    Zhang, Hong
    Reis-Filho, Jorge
    Wen, Hannah
    MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 173 - 175
  • [33] Interobserver Variation of PD-L1 SP142 Immunohistochemistry Interpretation in Breast Carcinoma
    Hoda, Raza S.
    Brogi, Edi
    D'Alfonso, Timothy M.
    Grabenstetter, Anne
    Giri, Dilip
    Hanna, Matthew G.
    Kuba, M. Gabriela
    Murray, Melissa P.
    Vallejo, Christina E.
    Zhang, Hong
    Reis-Filho, Jorge S.
    Wen, Hannah Y.
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2021, 145 (09) : 1132 - 1137
  • [34] Development of a PD-L1 companion diagnostic IHC assay (SP142) for atezolizumab
    Boyd, Zachary S.
    Smith, Dustin
    Baker, Brian
    Vennapusa, Bharathi
    Koeppen, Hartmut
    Kowanetz, Marcin
    Mariathasan, Sanjeev
    Bruey, Jean-Marie
    Mackey, Howard
    Fine, Gregg
    Mocci, Simonetta
    Hegde, Priti
    Williams, J. Andrew
    McCaffery, Ian
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (01)
  • [35] PD-L1 IHC validation and comparison of E1L3N & SP142 mAbs in melanoma
    Schats, K.
    van Vre, E.
    De Schepper, S.
    Neyns, B.
    De Meester, I.
    Kockx, M.
    ANNALS OF ONCOLOGY, 2015, 26 : 8 - 8
  • [36] PD-L1 (SP263) staining of fine needle aspirate FFPE samples in NSCLC
    Hayden, D.
    Roland, B.
    Saufkie, K.
    Largo, S.
    Ahmadi, P.
    Vasquez, M.
    Newell, A. E. Hanlon
    Schnittker, K.
    ANNALS OF ONCOLOGY, 2020, 31 : S1113 - S1113
  • [37] Expression of PD-L1 using SP142 CDx in triple negative breast cancer
    Al-Jussani, Ghada N.
    Dabbagh, Tamara Z.
    Al-Rimawi, Dalia
    Sughayer, Maher A.
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2021, 51
  • [38] Concordance of Programmed Death-Ligand 1 Expression between SP142 and 22C3/SP263 Assays in Triple-Negative Breast Cancer
    Lee, Seung Eun
    Park, Ha Young
    Lim, So Dug
    Han, Hye Seung
    Yoo, Young Bum
    Kim, Wan Seop
    JOURNAL OF BREAST CANCER, 2020, 23 (03) : 303 - 313
  • [39] Immunohistochemical Assessment of the Diagnostic Utility of PD-L1 (Clone SP142) for Methotrexate-Associated Lymphoproliferative Disorders With an Emphasis of Neoplastic PD-L1 (Clone SP142)-Positive Classic Hodgkin Lymphoma Type
    Kohno, Kei
    Suzuki, Yuka
    Elsayed, Ahmed A.
    Sakakibara, Ayako
    Takahara, Taishi
    Satou, Akira
    Kato, Seiichi
    Nakamura, Shigeo
    Asano, Naoko
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2020, 153 (05) : 571 - 582
  • [40] Comparison of 22C3 PharmDx and SP263 Assays to Test PD-L1 Expression in NSCLC
    Sughayer, Maher A.
    Alnaimy, Farah
    Alsughayer, Anas M.
    Qamhia, Naim
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2019, 27 (09) : 663 - 666
12345